obeticholic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5155 459789-99-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • obeticholic acid
  • ocaliva
  • 6-ECDCA
  • 6ECDCA
  • INT-747
obeticholic acid is an agonist for FXR, a nuclear receptor expressed in the liver and intestine
  • Molecular weight: 420.63
  • Formula: C26H44O4
  • CLOGP: 5.36
  • LIPINSKI: 1
  • HAC: 4
  • HDO: 3
  • TPSA: 77.76
  • ALOGS: -4.58
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Dec. 12, 2016 EMA Intercept Pharma Ltd
May 27, 2016 FDA INTERCEPT PHARMACEUTICALS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 1505.08 29.80 657 4128 360796 63123441
Therapy cessation 247.00 29.80 91 4694 30366 63453871
Hospitalisation 210.19 29.80 110 4675 84971 63399266
Therapy interrupted 171.08 29.80 71 4714 32384 63451853
Product dose omission issue 160.77 29.80 136 4649 234177 63250060
Blood alkaline phosphatase abnormal 140.89 29.80 26 4759 539 63483698
Hepatic cirrhosis 103.54 29.80 46 4739 24688 63459549
Blood alkaline phosphatase increased 93.07 29.80 51 4734 42916 63441321
Fatigue 92.30 29.80 204 4581 887824 62596413
Hepatic fibrosis 83.57 29.80 24 4761 3628 63480609
Insurance issue 75.34 29.80 25 4760 6096 63478141
Emergency care 68.69 29.80 16 4769 1058 63483179
Constipation 58.39 29.80 78 4707 224865 63259372
Portal hypertension 56.76 29.80 18 4767 3801 63480436
Varices oesophageal 55.89 29.80 17 4768 3131 63481106
Death 50.25 29.80 96 4689 374285 63109952
Rehabilitation therapy 42.97 29.80 12 4773 1638 63482599
Dry skin 42.87 29.80 35 4750 56852 63427385
Therapy change 37.80 29.80 15 4770 6066 63478171
Splenomegaly 32.00 29.80 16 4769 11141 63473096

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 163.29 42.26 57 272 141924 34814678
Hospitalisation 42.74 42.26 17 312 56885 34899717

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 1312.09 30.20 529 3129 394119 79346611
Therapy cessation 180.57 30.20 67 3591 37495 79703235
Product dose omission issue 127.80 30.20 99 3559 247438 79493292
Therapy interrupted 108.22 30.20 44 3614 31297 79709433
Fatigue 89.43 30.20 155 3503 929572 78811158
Blood alkaline phosphatase abnormal 85.77 30.20 17 3641 865 79739865
Hepatic cirrhosis 84.12 30.20 38 3620 34868 79705862
Blood alkaline phosphatase increased 75.79 30.20 43 3615 63621 79677109
Hospitalisation 72.14 30.20 48 3610 94188 79646542
Insurance issue 50.03 30.20 16 3642 5717 79735013
Varices oesophageal 45.30 30.20 15 3643 5976 79734754
Constipation 43.59 30.20 59 3599 282991 79457739
Hepatic fibrosis 38.66 30.20 14 3644 7266 79733464
Death 32.99 30.20 77 3581 566437 79174293
Portal hypertension 31.61 30.20 12 3646 7096 79733634
Cholelithiasis 31.30 30.20 23 3635 52641 79688089

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A05AA04 ALIMENTARY TRACT AND METABOLISM
BILE AND LIVER THERAPY
BILE THERAPY
Bile acids and derivatives
FDA MoA N0000192560 Farnesoid X Receptor Agonists
FDA EPC N0000192561 Farnesoid X Receptor Agonist
CHEBI has role CHEBI:62868 hepatoprotective agents
CHEBI has role CHEBI:132972 farnesoid X receptor agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Primary cholangitis indication 17266006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.92 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 10047117 Sept. 6, 2033 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 10047117 Sept. 6, 2033 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 10758549 April 26, 2036 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 10758549 April 26, 2036 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL May 27, 2023 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL May 27, 2023 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Bile acid receptor Nuclear hormone receptor AGONIST EC50 7.00 SCIENTIFIC LITERATURE DRUG LABEL
G-protein coupled bile acid receptor 1 GPCR EC50 7 CHEMBL

External reference:

IDSource
0462Z4S4OZ UNII
4035786 VANDF
C1143018 UMLSCUI
CHEBI:43602 CHEBI
CHEMBL566315 ChEMBL_ID
D09360 KEGG_DRUG
447715 PUBCHEM_CID
DB05990 DRUGBANK_ID
9084 INN_ID
3435 IUPHAR_LIGAND_ID
1798288 RXNORM
241391 MMSL
31698 MMSL
d08442 MMSL
016875 NDDF
720257002 SNOMEDCT_US
763557003 SNOMEDCT_US
CHC PDB_CHEM_ID
IU6 PDB_CHEM_ID
C464660 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-005 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-005 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-005 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-010 TABLET, FILM COATED 10 mg ORAL NDA 32 sections
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-010 TABLET, FILM COATED 10 mg ORAL NDA 32 sections
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-010 TABLET, FILM COATED 10 mg ORAL NDA 32 sections